Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown. METHODS: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors). RESULTS: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. CONCLUSIONS: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Examination of the lymphocytes that correlated with such beneficial outcomes has repeatedly implicated effector and memory CD8 + T cell and NK cell populations (136-141).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [136]
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Research works printed but not linked: 2
- 10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · DOI · Paper page
- 10.1002/(sici)1097-0215(19990621)84:3<326::aid-ijc22>3.0.co;2-k · DOI · Paper page
Cited by
Items 201–300 of 1,001
Perrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210
Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03205 · Cited by 210
“Extensive literature demonstrated a favorable prognostic impact of the in situ immune-cell infiltrate in tumors.(1,7-19) In CC we have shown that time to recurrence (TTR) and overall survival (OS) strongly correlated with the strength of in situ adaptive immune reaction(9,14,18,20,21) at the center of tumor (CT) and i…”
BackgroundSelf-citationSuzuki, K., Kadota, K., Sima, C. S., Nitadori, J.-I., Rusch, V. W., Travis, W. D., Sadelain, M., & Adusumilli, P. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2052 · Cited by 209
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Self-citationAntibody-based proteomics: fast-tracking molecular diagnostics in oncology
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., & Gallagher, W. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2902 · Cited by 208
Alexe, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesirov, J. P., DeLisi, C., Harris, L., Barnard, N., Martel, M., Levine, A. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0539 · Cited by 207
Immune responses to malignancies
Whiteside, T. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.045 · Cited by 204
“Thus increased densities of T-cell infiltrates with a high proportion of CD8(1) T cells within primary colorectal carcinomas were associated with a significant protection against tumor recurrence.(11) Furthermore, the same group also showed that coexpression of genes mediating cytotoxicity and TH1 adaptive immune resp…”
BackgroundBiology and clinical relevance of granulysin
Krensky, A. M., & Clayberger, C. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01218.x · Cited by 203
“found low granulysin expression in effector memory T cells in tumor infiltrates to correlate early metastasis and poor survival rates, while high levels of granulysin correlated with good outcomes in colorectal carcinoma (26).”
BackgroundMarchesi, F., Piemonti, L., Fedele, G., Destro, A., Roncalli, M., Albarello, L., Doglioni, C., Anselmo, A., Doni, A., Bianchi, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1810 · Cited by 202
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“Expression profiles associated with antitumor T cell cytokines (IFN-γ) and effector molecules (granulysin and granzyme B) are also independent prognosticators of decreased early metastasis in colon cancer (37).”
BackgroundTumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
“In colorectal cancer, immune effectors may protect against disease progression, since the lack of immune infiltration is associated with the development of metastases [22].”
BackgroundInteractions between immunity, proliferation and molecular subtype in breast cancer prognosis
Nagalla, S., Chou, J. W., Willingham, M. C., Ruiz, J., Vaughn, J. P., Dubey, P., Lash, T. L., Hamilton-Dutoit, S. J., Bergh, J., Sotiriou, C., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r34 · Cited by 196
“This association has been rigorously documented for a number of malignancies, most notably cancers of the skin [38,39], ovary [40,41], colon [42-45] and breast [20-22], underscoring the broad protective effects of anti-cancer immunosurveillance [46-48].”
BackgroundExisting and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells
Zipin-Roitman, A., Meshel, T., Sagi-Assif, O., Shalmon, B., Avivi, C., Pfeffer, R. M., Witz, I. P., & Ben-Baruch, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3087 · Cited by 194
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Natural immunity to cancer in humans
Bindea, G., Mlecnik, B., Fridman, W.-H., Pagès, F., & Galon, J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.006 · Cited by 192
Self-citationTumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories
Man, Y.-G., Stojadinovic, A., Mason, J., Avital, I., Bilchik, A., Bruecher, B., Protic, M., Nissan, A., Izadjoo, M., Zhang, X., et al. (2013) · Journal of Cancer · doi:10.7150/jca.5482 · Cited by 192
“The main strength of this hypothesis is that it is based on both clinical and laboratory data and that Treg-cell induced immune suppression has been well documented in multiple types of human cancer and diseases [100-104].”
BackgroundOccurrence and significance of tumor‐associated neutrophils in patients with colorectal cancer
Galdiero, M. R., Bianchi, P., Grizzi, F., Di Caro, G., Basso, G., Ponzetta, A., Bonavita, E., Barbagallo, M., Tartari, S., Polentarutti, N., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30076 · Cited by 192
Zeng, D.-Q., Yu, Y.-F., Ou, Q.-Y., Li, X.-Y., Zhong, R.-Z., Xie, C.-M., & Hu, Q.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.7282 · Cited by 192
“In particular, the intensity of the tumoral immune response influences the effectiveness of cancer therapy; levels of tumor-infiltrating lymphocytes (TILs), such as CD3+, CD4+, CD8+, and factor forkhead box P3 (FoxP3+) T cells were proved to be an expression of immune response that is associated with patient survival…”
BackgroundDefining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
Mahajan, U. M., Langhoff, E., Goni, E., Costello, E., Greenhalf, W., Halloran, C., Ormanns, S., Kruger, S., Boeck, S., Ribback, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.009 · Cited by 192
Bai, Z., Zhou, Y., Ye, Z., Xiong, J., Lan, H., & Wang, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808964 · Cited by 189
“The role of CD8 CTLs in prognosis was first analyzed in a large cohort of CRC more than 10 years ago (24, 32).”
BackgroundLévy, J., Cacheux, W., Bara, M. A., L’Hermitte, A., Lepage, P., Fraudeau, M., Trentesaux, C., Lemarchand, J., Durand, A., Crain, A.-M., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3206 · Cited by 189
T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses
Zhu, Y., Ju, S., Chen, E., Dai, S., Li, C., Morel, P., Liu, L., Zhang, X., & Lu, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000749 · Cited by 189
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy
Medler, T. R., Murugan, D., Horton, W., Kumar, S., Cotechini, T., Forsyth, A. M., Leyshock, P., Leitenberger, J. J., Kulesz-Martin, M., Margolin, A. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.003 · Cited by 188
Role of Cancer Microenvironment in Metastasis: Focus on Colon Cancer
Gout, S., & Huot, J. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0007-2 · Cited by 187
“In particular, the presence of intra-tumoural T cells correlates with a better clinical outcome in advanced colorectal carcinoma [18, 19].”
BackgroundStrategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
Donnem, T., Kilvaer, T. K., Andersen, S., Richardsen, E., Paulsen, E. E., Hald, S. M., Al-Saad, S., Brustugun, O. T., Helland, A., Lund-Iversen, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv560 · Cited by 187
“As this study included stage I adenocarcinomas patients only, and it showed highly significant impact in colorectal cancer, CD45RO deserves to be further elucidated in NSCLC [29, 30].”
BackgroundPatterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee, L. H., Cavalcanti, M. S., Segal, N. H., Hechtman, J. F., Weiser, M. R., Smith, J. J., Garcia-Aguilar, J., Sadot, E., Ntiamoah, P., Markowitz, A. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.139 · Cited by 186
Schetter, A. J., Nguyen, G. H., Bowman, E. D., Mathé, E. A., Yuen, S. T., Hawkes, J. E., Croce, C. M., Leung, S. Y., & Harris, C. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0627 · Cited by 185
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
Yang, I., Tihan, T., Han, S. J., Wrensch, M. R., Wiencke, J., Sughrue, M. E., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.031 · Cited by 181
“Additional cancer studies into the presence of infiltrating T-cells have been investigated in several neoplasms such as melanoma [19-21], ovarian cancer [22-24], and colorectal cancer [25-28], but unlike in these lesions, the clinical outcome of glioma patients with CD8+ Tcell infiltrate has remained uncertain [1].”
Wu, V., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 179
“Indeed, increased CXCL9 and CXLC10 and tumor-infiltrating CD8 T cells correlates with improved survival and decreased cancer metastasis (170, 171).”
BackgroundAssessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
Faraj, S. F., Munari, E., Guner, G., Taube, J., Anders, R., Hicks, J., Meeker, A., Schoenberg, M., Bivalacqua, T., Drake, C., et al. (2015) · Urology · doi:10.1016/j.urology.2014.10.020 · Cited by 178
Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
Lee, J. H. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.35 · Cited by 176
“A lymphocytic reaction to colorectal cancer has been associated with longer survival in patients with colorectal cancer,(1-5) and it may be an indicator of a host immune response to tumor cells that leads to improved survival.(13,14) Despite evidence supporting the prognostic value of the TIL grade, the method has not…”
ResultPrognostic Immune Markers in Non–Small Cell Lung Cancer
Suzuki, K., Kachala, S. S., Kadota, K., Shen, R., Mo, Q., Beer, D. G., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2805 · Cited by 176
Ling, L., Lin, Y., Zheng, W., Hong, S., Tang, X., Zhao, P., Li, M., Ni, J., Li, C., Wang, L., et al. (2016) · Scientific Reports · doi:10.1038/srep20358 · Cited by 176
Roxburgh, C. S. D., & McMillan, D. C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.001 · Cited by 175
Hiraoka, N., Yamazaki–Itoh, R., Ino, Y., Mizuguchi, Y., Yamada, T., Hirohashi, S., & Kanai, Y. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.009 · Cited by 175
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis
Yu, A. I., Zhao, L., Eaton, K. A., Ho, S., Chen, J., Poe, S., Becker, J., Gonzalez, A., McKinstry, D., Hasso, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.035 · Cited by 173
Ling, K. L., Pratap, S., Bates, G. J., Singh, B., Mortensen, N. J. M., George, B. D., Warren, B. F., Piris, J., Roncador, G., Fox, S. B., et al. (2007) · PubMed · Cited by 191
Katz, S. C., Bamboat, Z. M., Maker, A. V., Shia, J., Pillarisetty, V. G., Yopp, A. C., Hedvat, C. V., Gonen, M., Jarnagin, W. R., Fong, Y., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2668-9 · Cited by 171
“Presently, we confirmed that CRCLM CD8 T cell infiltration correlates with survival time following resection in a larger, more recent series of patients, consistent with what has been reported for primary colorectal cancer.(3,4,22) These findings fit well with the role cytotoxic CD8 T cells play as direct mediators of…”
ResultSTING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Curran, E., Chen, X., Corrales, L., Kline, D. E., Dubensky, T. W., Duttagupta, P., Kortylewski, M., & Kline, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.023 · Cited by 170
Ascierto, M. L., Kmieciak, M., Idowu, M. O., Manjili, R., Zhao, Y., Grimes, M., Dumur, C., Wang, E., Ramakrishnan, V., Wang, X.-Y., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1470-x · Cited by 167
“A few reports with special focus on infiltrating cells emphasized mainly particular immune cells such as lymphocytes or tumor-associated macrophages [9–11], rather than a network of immune function genes.”
BackgroundA Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
Deschoolmeester, V., Baay, M., Specenier, P., Lardon, F., & Vermorken, J. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0025 · Cited by 166
Tougeron, D., Mouillet, G., Trouilloud, I., Lecomte, T., Coriat, R., Aparicio, T., Des Guetz, G., Lécaille, C., Artru, P., Sickersen, G., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv438 · Cited by 164
B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis
Yang, C., Lee, H., Pal, S., Jove, V., Deng, J., Zhang, W., Hoon, D. S. B., Wakabayashi, M., Forman, S., & Yu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064159 · Cited by 164
“For example, the density of T cells in colorectal tumor tissues represents a better prognostic indicator for patient outcome than current staging systems [2,3].”
BackgroundUse of tumour-responsive T cells as cancer treatment
Disis, M. L., Bernhard, H., & Jaffee, E. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60404-9 · Cited by 164
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
“As an increase in the number of tumor-infiltrating CD8 + T cells improves clinical outcome of human colorectal cancer 1,22–24 , it is possible that tumor-infiltrating T cell deletion with apoptosis imposes immune dysfunction.”
Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin
Tewary, P., Yang, D., de la Rosa, G., Li, Y., Finn, M. W., Krensky, A. M., Clayberger, C., & Oppenheim, J. J. (2010) · Blood · doi:10.1182/blood-2010-03-273953 · Cited by 162
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Hegmans, J. P. J. J., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00135305 · Cited by 162
“It can also negatively impact on tumour growth; for example, the presence of macrophages in tumour islets of nonsmall cell lung cancer (NSCLC) and the presence of infiltrating effector memory T-cells in colorectal cancer is associated with an increased survival [10, 11 ].”
BackgroundToiyama, Y., Yasuda, H., Saigusa, S., Tanaka, K., Inoue, Y., Goel, A., & Kusunoki, M. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt282 · Cited by 161
“In fact, increased immune cells in CRC are reportedly associated with better survival (38).”
BackgroundHalim, L., Romano, M., McGregor, R., Correa, I., Pavlidis, P., Grageda, N., Hoong, S.-J., Yuksel, M., Jassem, W., Hannen, R. F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.079 · Cited by 161
“In this pathology, Th1 responses allow secretion of cytokines that promote the antitumor response (Pagès et al., 2005), whereas Th2 responses favor tumor growth (Hou et al., 2013; Pernot et al., 2014).”
BackgroundDetailed analysis of inflammatory cell infiltration in colorectal cancer
Väyrynen, J. P., Tuomisto, A., Klintrup, K., Mäkelä, J., Karttunen, T. J., & Mäkinen, M. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.508 · Cited by 158
“…concern (Galon et al, 2012; Roxburgh and McMillan, 2012), and so far, none of the proposed immunohistochemical cell markers (Naito et al, 1998; Pages et al, 2005; Galon et al, 2006; Väyrynen et al, 2012b) or inflammatory classifications based on inspecting haematoxylin and eosin (H&E) slides…”
BackgroundSun, J., Chen, L.-J., Zhang, G.-B., Jiang, J.-T., Zhu, M., Tan, Y., Wang, H.-T., Lu, B.-F., & Zhang, X.-G. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0841-1 · Cited by 159
“It is noteworthy that the type, density and location of immune cells in CRC tissues are significantly associated with the early metastatic invasion and the prolonged survival [ 4 , 39] and the presence of Th1 cells is an independent prognostic marker for patient survival [39].”
BackgroundSubgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
Auclin, E., Zaanan, A., Vernerey, D., Douard, R., Gallois, C., Laurent-Puig, P., Bonnetain, F., & Taieb, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx030 · Cited by 159
Wu, L., Deng, W.-W., Huang, C.-F., Bu, L.-L., Yu, G.-T., Mao, L., Zhang, W.-F., Liu, B., & Sun, Z.-J. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1968-0 · Cited by 158
“1 3 It has been reported that tumor-infiltrating CD8+ T cells are associated with prolonged survival in various tumor types such as colorectal cancer [28], endometrial adenocarcinoma [29], ovarian cancer [30], renal cell cancer [31] and esophageal cancer [32].”
BackgroundEnhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 158
Toor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
“Therefore, evidence of an active immune response in the CRC TME was shown to be associated with prolonged survival (39).”
BackgroundHuang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Kirilovsky, A., Marliot, F., El Sissy, C., Haicheur, N., Galon, J., & Pagès, F. (2016) · International Immunology · doi:10.1093/intimm/dxw021 · Cited by 157
Self-citationDillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 210
“Their presence in locally invasive colorectal cancer is associated with a better survival compared to patients whose tumors lack such cells.(472) Such cells can induce autoimmunity against tumor-associated antigens,(473) but are inhibited by CD4þ CD25þ T-regulatory cells.”
BackgroundReport From the Jerusalem Workshop on Lynch Syndrome-Hereditary Nonpolyposis Colorectal Cancer
Boland, C. R., & Shike, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.024 · Cited by 162
NK cells and T cells cooperate during the clinical course of colorectal cancer
Sconocchia, G., Eppenberger, S., Spagnoli, G. C., Tornillo, L., Droeser, R., Caratelli, S., Ferrelli, F., Coppola, A., Arriga, R., Lauro, D., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.952197 · Cited by 155
Colitis-Associated Colorectal Cancer Driven by T-bet Deficiency in Dendritic Cells
Garrett, W. S., Punit, S., Gallini, C. A., Michaud, M., Zhang, D., Sigrist, K. S., Lord, G. M., Glickman, J. N., & Glimcher, L. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.015 · Cited by 155
“This observation coupled with the finding that increased levels of T-bet in human colorectal tumors correlate with increased patient survival spurred us to determine if TRUC mice, whose colitis is mechanistically distinct from other IBD models, would develop caCRC (Pages et al., 2005).”
Cancer immune contexture and immunotherapy
Becht, É., Giraldo, N. A., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.009 · Cited by 178
“com intratumoral memory T cells correlates with patients’ longer disease-free (DFS) and overall (OS) survivals [2], confirming a previous report in ovarian cancer [3 ].”
ResultSelf-citationChemokines and Chemokine Receptors: Orchestrating Tumor Metastasization
Marcuzzi, E., Angioni, R., Molon, B., & Calì, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010096 · Cited by 173
“CXCR3 CXCL9 CXCL10 CXCL11 CXCL4L1 Melanoma [18,34] T cells [61,62] Colorectal cancer [8,18,34,35] NKT cells [63,64] Leukemia [18,34] Platelets [52] Breast cancer [36] Renal cancer [18,34]”
BackgroundCo-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Liu, J., Zhao, Z., Qiu, N., Zhou, Q., Wang, G., Jiang, H., Piao, Y., Zhou, Z., Tang, J., & Shen, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-22407-6 · Cited by 164
Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma
Mina, M., Boldrini, R., Citti, A., Romania, P., D’Alicandro, V., Ioris, M. A. D., Castellano, A., Furlanello, C., Locatelli, F., & Fruci, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019981 · Cited by 163
Tougeron, D., Fauquembergue, É., Rouquette, A., Pessot, F. L., Sesboüé, R., Laurent, M., Berthet, P., Mauillon, J., Fiore, F. D., Sabourin, J., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.80 · Cited by 178
Adoptive immunotherapy for cancer
Ruella, M., & Kalos, M. D. (2013) · Immunological Reviews · doi:10.1111/imr.12136 · Cited by 168
“To enumerate a few examples, the presence of TILs in tumor specimens is correlated with better clinical outcome in cancer patients (302, 303).”
ResultHan, L. Y., Fletcher, M. S., Urbauer, D. L., Mueller, P., Landen, C. N., Kamat, A. A., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Deavers, M. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4433 · Cited by 153
Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma
Molodtsov, A. K., Khatwani, N., Vella, J. L., Lewis, K. A., Zhao, Y., Han, J., Sullivan, D. E., Searles, T. G., Preiss, N. K., Shabaneh, T. B., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.019 · Cited by 163
Wang, S. C., Chou, J. F., Strong, V. E. M., Brennan, M. F., Capanu, M., & Coit, D. G. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001189 · Cited by 150
Zumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2015) · Oncotarget · doi:10.18632/oncotarget.3205 · Cited by 151
“the type and density of tumor infiltrating T-cells varies among colorectal tumors and affects metastasis and disease [2-8].”
BackgroundResultInfluentialRobert, C., Schadendorf, D., Messina, M., Hodi, F. S., & O'Day, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3080 · Cited by 151
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells
Hamaidi, I., Zhang, L., Kim, N., Wang, M.-H., Iclozan, C., Fang, B., Liu, M., Koomen, J. M., Berglund, A., Yoder, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.008 · Cited by 157
“, 2018) and their high frequency correlates with favorable prognosis in cancer patients (Pages et al., 2005).”
BackgroundQuantitative evaluation of vimentin expression in tumour stroma of colorectal cancer
Ngan, C. Y., Yamamoto, H., Seshimo, I., Tsujino, T., Man-i, M., Ikeda, J.-I., Konishi, K., Takemasa, I., Ikeda, M., Sekimoto, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603651 · Cited by 150
“However, increased immune cells in CRC are reportedly associated with better survival (Pages et al, 2005).”
BackgroundWatanabe, Y., Katou, F., Ohtani, H., Nakayama, T., Yoshie, O., & Hashimoto, K. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.12.015 · Cited by 168
Dulphy, N., Haas, P., Busson, M., Belhadj, S., de Latour, R. P., Robin, M., Carmagnat, M., Loiseau, P., Tamouza, R., Scieux, C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2227 · Cited by 156
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Dendritic cell derived-exosomes: biology and clinical implementations
Chaput, N., Flament, C., Viaud, S., Taieb, J., Roux, S., Spatz, A., André, F., LePecq, J.-B., Boussac, M., Garin, J., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0206094 · Cited by 148
“vival in cancer-bearing patients [56–58].”
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Kao, J., Ko, E. C., Eisenstein, S. G., Sikora, A. G., Fu, S., & Chen, S. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.004 · Cited by 151
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Takahashi, H., Sakakura, K., Kawabata‐Iwakawa, R., Rokudai, S., Toyoda, M., Nishiyama, M., & Chikamatsu, K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1742-0 · Cited by 166
“T cells predominantly orchestrate the host immune system, and the T-cell infiltration of tumor lesions has been reported to correlate with improved prognoses in various types of cancers [10,11].”
BackgroundSerum soluble interleukin 2 receptor α in human cancer of adults and children: a review
Bień, E., & Balcerska, A. (2008) · Biomarkers · doi:10.1080/13547500701674063 · Cited by 156
“There is also evidence that the presence of tumour-infiltrating T cells is associated with a favourable prognosis in several types of cancer (Trentin et al. 1994, Diefenbach & Raulet 2002, Pages et al. 2005).”
BackgroundTranscriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies
Petitprez, F., Vano, Y. A., Becht, É., Giraldo, N. A., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2058-z · Cited by 157
“The composition of the TME, at each stage of a cancer, untreated or even after chemo-, radio-, or immunotherapy often represents the strongest predictor for disease control [5, 6].”
BackgroundSelf-citationInterferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 150
“IRF1 activation and IFN-γ signaling were enriched in cytotoxic Th1 responses to prevent early tumor cell dissemination (149), suggesting that immunity actively prevents tumor dissemination.”
BackgroundTumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Reissfelder, C., Stamova, S., Gossmann, C., Braun, M., Bonertz, A., Walliczek, U., Grimm, M., Rahbari, N. N., Koch, M., Saadati, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74894 · Cited by 142
“Indeed, Pages et al. demonstrated that CXCL9 expression correlated with increased TC infiltrates and type 1 TC signatures and with improved prognosis of patients with CRC (4, 8).”
Baker, K., Rath, T., Flak, M. B., Arthur, J. C., Chen, Z., Glickman, J. N., Zlobec, I., Karamitopoulou, E., Stachler, M. D., Odze, R. D., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.003 · Cited by 141
“It is well accepted that cytotoxic CD8+ T cell-mediated responses are critical for efficient anti-tumor immunity (Pages et al., 2005) and FcRn has recently been shown to enable highly efficient cross-presentation of IgG-complexed antigens by CD8−CD11b+ DC (Baker et al., 2011).”
InfluentialDeng, L., Zhang, H., Luan, Y., Zhang, J., Xing, Q. R., Dong, S., Wu, X., Liu, M., & Wang, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1073 · Cited by 155
Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 148
“In colorectal cancer patients, the infiltration of T cells in the primary tumor was associated with reduced probability of tumor dissemination, suggesting an anti-tumor role of the adaptive immune system in the early stages of the metastatic process (Page ̀ s et al., 2005).”
Cui, J.-H., Lin, K.-R., Yuan, S.-H., Jin, Y.-B., Chen, X., Su, X.-K., Jiang, J., Pan, Y.-M., Mao, S.-L., Mao, X., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02729 · Cited by 181
“Due to distinct degree of TCR repertoire overlap between tumor tissues and paired sentinel lymph nodes were observed in these CC patients (Figure 6E), we hypothesized that these overlapping clonotypes identified in sentinel lymph nodes might represent a population of effector memory T-cells that egressed from the tumo…”
Cézé, N., Thibault, G., Goujon, G., Viguier, J., Watier, H., Dorval, E. D., & Lecomte, T. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1610-3 · Cited by 153
Cancer Immunotherapy: Accomplishments to Date and Future Promise
Helmy, K. Y., Patel, S. A., Nahas, G. R., & Rameshwar, P. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.88 · Cited by 156
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 162
Sun, H.-L., Xin Min, Z. H. O. U., Xue, Y., Wang, K., Shen, Y., Mao, J., Guo, H., & Miao, Z. (2012) · PubMed · doi:10.3748/wjg.v18.i25.3303 · Cited by 128
Consensus nomenclature for CD8+T cell phenotypes in cancer
Apetoh, L., Smyth, M. J., Drake, C. G., Abastado, J.-P., Apte, R. N., Ayyoub, M., Blay, J.-Y., Bonneville, M., Butterfield, L. H., Caignard, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998538 · Cited by 138
Self-citationMuthuswamy, R., Berk, E., Junecko, B. F., Zeh, H. J., Zureikat, A. H., Normolle, D., Luong, T. M., Reinhart, T. A., Bartlett, D. L., & Kalinski, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4136 · Cited by 138
“The ability of CD8+ T cells to infiltrate cancer lesions is essential for anti-tumor immunity, as evidenced by studies highlighting the prognostic value of effector T (Teff) cells in multiple cancer types, including colorectal cancer (CRC) (1-4).”
Influential
Metadata
- Authors
- Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., Meatchi, T., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Galon, J.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Graz University of Technology (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-22
- Volume
- 353
- Issue
- 25
- Pages
- 2654-2666
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096151993
- Semantic Scholar
- 608c79dfb95b1632f3cda7f427350880ee435e8a
- Cited by
- 2,135
- References
- 32
- Citations by year
- 2026: 27 · 2025: 57 · 2024: 66 · 2023: 118 · 2022: 117 · 2021: 141 · 2020: 130 · 2019: 123 · 2018: 123 · 2017: 136 · 2016: 135 · 2015: 145 · 2014: 115 · 2013: 135 · 2012: 108
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- colorectal cancer, effector memory T cells, tumor-infiltrating lymphocytes, CD8+ T cells, CD45RO+ memory T cells, T-cell markers, lymphatic invasion, perineural invasion, interferon-gamma, granzyme B, granulysin, IRF1, disease-free survival, overall survival, antitumor immunity
- MeSH terms
- Analysis of Variance, Embolism, Flow Cytometry, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, RNA, Messenger, T-Lymphocytes, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Survival Analysis, Polymerase Chain Reaction, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Microarray Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.